GLPwatch
Trials (2167)
Page 2 of 37.
- GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
- A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
- A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus
- Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.
- Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function
- Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
- DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2
- Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)
- Tirzepatide vs Liraglutide in Bone
- A Comparison of Exenatide and Insulin Glargine
- Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility
- DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy
- Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
- Real-World Outcomes of Tirzepatide in Pakistani Adults With Obesity, Prediabetes, and Type 2 Diabetes
- A Study of LY2189265 in Japanese Patients With Type 2 Diabetes
- Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
- Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.
- Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.
- A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
- A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
- Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
- A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
- Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)
- Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent
- Semaglutide in Nonalcoholic Fatty Liver Disease
- Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease
- A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
- Incretin and KATP Channels
- A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
- Semaglutide and Cognition in Healthy Volunteers
- GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis
- GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward
- Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)
- Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting
- Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.
- Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
- Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals
- A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
- Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy
- Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists
- Exenatide in Extreme Pediatric Obesity
- Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
- Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial
- A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
- Bariatric Surgery Combined With GLP-1 Receptor Agonists Study
- Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice
- SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes
- A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
- Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity
- Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
- Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus
- A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects
- GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial
- Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa
- Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
- Research on Effects of Drugs on Body Composition and Function With Imaging in Diabetes
- Effect of Renal Impairment on the Pharmacokinetics of NN9535
- The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
- A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.
- A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World